Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2025 Earnings Call Transcript

2025-05-06 21:19:04 ET

Ginkgo Bioworks Holdings, Inc. (DNA)

Q1 2025 Results Conference Call

May 06, 2025 05:00 PM ET

Company Participants

Daniel Marshall - Sr. Manager, Communications and Ownership

Jason Kelly - Co-Founder and Chief Executive Officer

Mark Dmytruk - Chief Financial Officer

Conference Call Participants

Michael Ryskin - Bank of America

Mark Massaro - BTIG

Tejas Savant - Morgan Stanley

Evie Koslosky - Goldman Sachs

Matt Larew - William Blair

Brendan Smith - TD Cowen

Presentation

Operator

[Call Starts Abruptly] live on air. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO. Thanks, as always, for joining us. We're looking forward to updating you on our progress.

As a reminder, during the presentation today, we'll be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the SEC to learn more about these risks and uncertainties, including our most recent 10-K.

Today, in addition to updating you on the quarter results, we're going to provide updates on our path towards adjusted EBITDA breakeven, traction with our government clients as well as new offerings and opportunities emerging for our tools businesses.

As usual, we'll end with a Q&A session and I'll take questions from analysts, investors and the public. You can submit those questions to us in advance via X, #GinkgoResults or e-mail, investors at investors@ginkgobioworks.com.

All right. Over to you, Jason.

Jason Kelly

Thanks, Daniel. We always start off with our mission here at Ginkgo, which is to make biology easier to engineer. And then we had three objectives. And I first showed these are close variants of these about a year ago when we announced that we were going to be doing a major restructuring of the Company.

And these three objectives were to reach adjusted EBITDA breakeven by the end of 2026. And importantly, doing that while maintaining a cash margin of safety. In other words, we didn't want to get in a position where we're going to need to fund raise when we didn't want to, right? We wanted to be doing that we needed to fund raise from a position of strength, but ideally not even need to fund raise.

Second, we wanted to cut costs while importantly, serving our current customers. We had a lot of amazing customers, large pharma, large ag biotechs, industrial biotechs as well as the government. We want to keep serving those customers well while at the same time focusing the Company.

And then finally, we wanted to expand the way we sold our platform, and I'll talk more about this in the strategic section. But from not just R&D solutions, where we do an end-to-end research project, but also directly as a tools business like a traditional CRO or an equipment vendor would. These were new ways to go to market to a wider set of potential customers than we had with our solutions business....

Read the full article on Seeking Alpha

For further details see: